Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Blister Pack Mandate Could Be Phased-In Based On Prescription Volume

Executive Summary

US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.

You may also be interested in...



Woodcock Highlights US FDA Opioid Plans Amid Sen. Manchin And Others’ Criticisms

The statement outlining opioid priorities in the FDA’s FY 2022 budget request comes on the heels of Sen. Manchin’s criticism of the acting commissioner and FDA opioid policy.

Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun

Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?

US FDA Needs ‘More Streamlined’ REMS Enforcement Authority, Inspector General Says

Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.

Related Content

Topics

UsernamePublicRestriction

Register

PS125386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel